The case for early detection

Nature Reviews Cancer

Volumn 3, Issue 4, 2003, Pages 243-252

  Etzioni, Ruth ^a   Urban, Nicole ^a   Ramsey, Scott ^a   McIntosh, Martin ^a   Schwartz, Stephen ^a   Reid, Brian ^a   Radich, Jerald ^a   Anderson, Garnet ^a   Hartwell, Leland ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CYTOTOXIC AGENT; GENOMIC DNA; PROSTATE SPECIFIC ANTIGEN; PROTEOME; TRASTUZUMAB; TUMOR MARKER;

ADVANCED CANCER; BREAST CANCER; CANCER CONTROL; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RESEARCH; CANCER SCREENING; CANCER SURVIVAL; CARCINOMA IN SITU; CASE CONTROL STUDY; CLINICAL TRIAL; CLUSTER ANALYSIS; COLORECTAL CANCER; COMPUTER MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DNA MICROARRAY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENE EXPRESSION; GENE TECHNOLOGY; GENOME; HEALTH CARE COST; HUMAN; LONGITUDINAL STUDY; LUNG CANCER; NONHUMAN; OVARY CANCER; PAPANICOLAOU TEST; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STATISTICAL ANALYSIS; TUMOR BIOPSY; UTERINE CERVIX CANCER; VALIDATION PROCESS; WART VIRUS; ECONOMICS; GENETIC MARKER; GENETICS; MASS SCREENING; METHODOLOGY; NEOPLASM; SURVIVAL; UNITED STATES;

CLINICAL TRIALS; GENETIC MARKERS; HUMANS; MASS SCREENING; NEOPLASMS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 0037648348     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1041     Document Type: Review

References (86)

1. National Cancer Institute. Surveillance Epidemiology and End Results Program [online], (cited 19 Nov 2002), 〈http://seer.cancer.gov/〉 (2002).
2. Winawer, S. J. et al. Prevention of colorectal cancer: guidelines based on new data. WHO Collaborating Center for the Prevention of Colorectal Cancer. Bull. World Health Organ. 73, 7-10 (1995).
3. Bell, R., Petticrew, M. & Sheldon, T. The performance of screening tests for ovarian cancer: results of a systematic review. Br. J. Obst. Gynaecol. 105, 1136-1147 (1998).
4. Henschke, C. Early Lung Cancer Action Project: overall design and findings from baseline screening. Cancer 89, 274-282 (2000).
5. Henschke, C. et al. Early Lung Cancer Action Project: initial findings on repeat screening. Cancer 92, 153-159 (2001).
6. Mahadevia, P. J. et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 289, 313-322 (2003).
7. Grann, V. R. & Neugut, A. I. Lung cancer screening at any price? JAMA 289, 357-358 (2003).
8. Etzioni, R. et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J. Natl Cancer Inst. 94, 981-990 (2002).
9. Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002). This article illustrates the potential utility of serum proteomics in developing sensitive and specific cancer screening tests.
10. Dhanasekaran, S. M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826 (2001).
11. Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054-1061 (2001). First paper to propose the classification of biomarker studies into five phases.
12. Pepe, M. S., Longton, G. M., Anderson, G. L. & Schummer, M. Selecting Differentially Expressed Genes from Microarray Experiments UW Biostatistics Working Paper Series. Working Paper 184 [online], (cited 24 Jan 2003), 〈http://www.bepress.com/uwbiostat/paper184〉 (2003).
13. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116-5121 (2001).
14. Yeung, K. Y., Haynor, D. R. & Ruzzo, W. L. Validating clustering for gene expression data. Bioinformatics 17, 309-318 (2001).
15. Yeung, K. Y., Fraley, C., Murua, A., Raftery, A. E. & Ruzzo, W. L. Model-based clustering and data transformations for gene expression data. Biornformatics 17, 977-987 (2001).
16. Hastie, T., Tibshirani, R. & Friedman, J. The Elements of Statistical Learning: Data Mining, Inference and Prediction (Springer-Verlag, New York, 2001).
17. Gann, P. H., Hennekens, C. H. & Stampfer, M. J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273, 289-294 (1995).
18. Mcintosh, M., Urban, N. & Karlan, B. Generating longitudinal screening algorithms using novel blomarkers for disease. Cancer Epidemiol. Biomarkers Prev. 11, 159-166 (2002)
19. Carter, H. B. & Pearson, J. D. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol. Clin. N. Am. 24, 333-338 (1997).
20. Polascik, T. J., Oesterling, J. E. & Partin, A. W. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J. Urol. 162, 293-306 (1999).
21. Skates, C. J., Pauler, D. K. & Jacobs, I. Screening based on the risk of cancer calculation from Bayesian hierarchical change-point models of longitudinal markers. J. Am. Stat. Assoc. 96, 429-439 (2001).
22. Carter, H. B. et al. Estimation of prostatic growth using sedal prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 52, 3323-3328 (1992).
23. Woods, W. G. et al. Screening of infants and mortality due to neuroblastoma. N. Engl. J. Med. 346, 1041-1046 (2002).
24. Farrow, D. C. & Vaughan, T. L. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 7, 322-327 (1996).
25. Conio, M. et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 48, 304-309 (2001).
26. Drewitz, D. J., Sampliner, R. E. & Garewal, H. S. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed for 8 years. Am. J. Gastroenterol. 92, 212-215 (1997).
27. Schnell, T. G. et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 120, 1607-1619 (2001).
28. Reld, B., Blount, P. & Rabinovitch, P. Biomarkers in Barrett's esophagus: a guideline for clinicians. Gastrointest. Clin. N. Am. (in the press).
29. Alikhan, M. et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest. Endosc. 50, 23-26 (1999).
30. Ofman, J. J. et al. The quality of care in Barrett's esophagus: endoscopist and pathologist practices. Am. J. Gastroenterol. 96, 876-881 (2001).
31. Macdonald, C. E., Wicks, A. C. & Playford, R. J. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 321, 1252-1255 (2000).
32. Connor, R. J., Prorok, P. C. & Weed, D. L. The case-control design and the assessment of the efficacy of cancer screening. J. Clin. Epidemiol. 44, 1215-1221 (1991).
33. Cronin, K. A., Weed, D. L., Connor, R. J. & Prorok, P. C. Case-control studies of cancer screening: theory and practice J. Natl Cancer Inst. 90, 498-504 (1998).
34. Weiss, N. S. Case-control studies of the efficacy of screening for cancer: can we earn them some respect J. Med. Screen. 4, 57-59 (1997). References 32-34 discuss the use of case-control studies for evaluating cancer screening with special attention to avoiding bias.
35. Etzioni, R. et al. Cancer surveillance series: interpreting trends in prostate cancer. Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J. Natl Cancer Inst. 91, 1033-1039 (1999).
36. Feuer, E. J., Mariotto, A. & Merrill, R. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. Cancer 95, 870-880 (2002).
37. Schatzkin, A. & Gail, M. The promise and peril of surrogate end points in cancer research. Nature Rev. Cancer 2, 19-27 (2002).
38. Hirsch, F. R. et al. IV International conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001. Lung Cancer 37, 325-344 (2002).
39. Friedman, D. R. & Dubin, N. Case-control evaluation of breast cancer screening efficacy. Am. J. Epidemiol. 133, 974-984 (1991).
40. Newcomb, P. A. et al. Breast self-examination in relation to the occurrence of advanced breast cancer. J. Natl Cancer Inst. 83, 260-265 (1991).
41. Hurley, S. F. & Kaldor, J. M. The benefits and risks of mammographic screening for breast cancer. Epidemiol. Rev. 14, 101-130 (1992).
42. Palli, D. et al. A case-control study of the efficacy of a nonrandomized breast cancer screening program in Florence (Italy). Int. J. Cancer 38, 501-504 (1986).
43. Selby, J. V., Fdedman, G. D., Quesenberry, C. P. Jr & Weiss, N. S. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N. Engl. J. Med. 326, 653-657 (1992).
44. Beemsterboer, P. M. et al. Prostate specific antigen testing and digital rectal examination before and dunng a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam. J. Urol. 164, 1216-1220 (2000).
45. Gohagan, J. K., Prorok, P. C., Hayes, R. B. & Kramer, B. S. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin. Trials 21, 251S-272S (2000).
46. Bartsch, G. et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austna. Urology 58, 417-424 (2001).
47. Lu-Yao, G. et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325, 740 (2002).
48. Oliver, S. E., May, M. T. & Gunnell, D. International trends in prostate-cancer mortality in the 'PSA ERA'. Int. J. Cancer 92, 893-898 (2001). References 48-48 are examples of recent population studies of PSA screening.
49. Harris, R. & Lohr, K. N. Screening for prostate cancer: an update of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. 137, 917-929 (2002).
50. Brown, M. L. & Fintor, L. Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Breast Cancer Res. Treat. 25, 113-118 (1993). Explores the reasons for variability in estimates of the cost-effectiveness of screening interventions.
51. Rosenquist, C. J. & Lindfors, K. K. Screening mammography beginning at age 40 years: a reappraisal of cost-effectiveness. Cancer 82, 2235-2240 (1998).
52. Salzmann, P., Kerlikowske, K. & Phillips, K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann. Intern. Med. 127, 955-965 (1997). References 51 and 52 show how different results of cost-effectiveness studies of the same intervention can be.
53. Pignone, M., Saha, S., Hoerger, T. & Mandelblatt, J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. Ann. Intern. Med. 137, 96-104 (2002).
54. van der Maas, P. J. et al. The cost-effectiveness of breast cancer screening. Int. J. Cancer 43, 1055-1060 (1989).
55. US Congress Office of Technology Assessment. Costs and Effectiveness of Prostate Cancer Screening in Elderly Men (US Government Printing Office, Washington DC, 1995).
56. Etzioni, R., Cha, R. & Cowen, M. E. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. J. Urol. 162, 741-748 (1999).
57. Ross, K. S., Carter, H. B., Pearson, J. D. & Guess, H. A. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 284, 1399-1405 (2000).
58. Boyes, D. A. The value of a pap smear program and suggestions for its implementation. Cancer 48, 613-621 (1981).
59. Christopherson, W. M., Parker, J. E. & Mendez, W. M. Cervix cancer death rates and mass cytologic screening. Cancer 26, 808-811 (1970).
60. Schiffman, M. H., Brinton, L. A., Devesa, S. S. & Fraumeni, J. F. Jr in Cancer Epidemiology and Prevention 2nd edn (eds Schottenfeld, D. & Fraumeni, J. F. Jr) 1090-1116 (Oxford Univ. Press, New York, 1996).
61. Parkin, D. M., Pisani, P. & Feday, J. Estimates of the worldwide frequency of eighteen major cancers in 1985. Int. J. Cancer 54, 594-606 (1993).
62. Cuzick, J. Time to consider HPV testing in cervical screening. Ann. Oncol. 12, 1511-1514 (2001).
63. Stoler, M. H. HPV for cervical cancer screening: is the era of the molecular pap smear upon us? J. Histochem. Cytochem. 49, 1197-1198 (2001).
64. Cuzick, J. et al. Human papillomavirus testing in primary cervical screening. Lancet 345, 1533-1536 (1995).
65. Kulasingam, S. L. et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivty, specificity, and frequency of referral. JAMA 288, 1749-1757 (2002).
66. Ratnam, S., Franco, E. L. & Ferenczy, A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol. Biomarkers Prev. 9, 945-951 (2000).
67. Woolas, R. P. et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol. Oncol. 59, 111-116 (1995).
68. Woolas, R. P. et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J. Natl Cancer Instit. 85, 1748-1751 (1993).
69. Bates, J. et al. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Eur. Resp. J. 10, 2535-2538 (1997).
70. Beduschi, M. C. & Oesterling, J. E. Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing. Urology 51, 98-109 (1998).
71. Brawer, M. K. Prostate-specific antigen: current status. CA Cancer J. Clin. 49, 264-281 (1999).
72. Catalona, W. J. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279, 1542-1547 (1998).
73. Gann, P. H., Ma, J., Catalona, W. J. & Stampfer, M. J. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J. Urol. 167, 2427-2434 (2002).
74. Zhang, Z. et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol. Oncol. 73, 56-61 (1999).
75. McIntosh, M. W. & Pepe, M. Combining several screening tests: optimality of the risk score. Biometrics 58, 657-664 (2002).
76. Baker, S. G. Identifying combinations of cancer markers for further study as triggers of early intervention. Biometrics 56, 1082-1087 (2000).
77. Etzioni, R., Kooperberg, C., Pepe, M. S., Smith, R. & Gann, P. H. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics (in the press). References 74-77 present new statistical methods for identifying optimal combinations of biomarkers.
78. Optenberg, S. A. et al. Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test. Urology 50, 665-672 (1997).
79. Urban, N., Drescher, C., Clarke, L. & Klviat, N. in Ovarian Cancer 5 (eds Sharp, F., Blackett, T., Berek, J. & Bast, R.) 217-229 (Isis Medical Media Ltd., Oxford, 1998).
80. Urban, N. et al. in Ovarian Cancer (ed. Jacobs, I.) 199-208 (Oxford Univ. Press, 2002).
81. Urban, N. Screening for ovarian cancer. BMJ 319, 1317-1318 (1999).
82. American Cancer Society. Costs of Cancer. 2002 [online], (cited 25 Jan 2003), 〈 http://www.cancer.org/docroot/MIT/contenL/MIT_3_2X_Costs_of_Cancer.asp〉 (2002).
83. Gold, M. E., Siegel, J. E., Russell, L. B. & Weintstein, M. C. Cost-Effectiveness in Health and Medicine (Oxford Univ. Press. New York, 1996).
84. US Congress Office of Technology Assessment Breast Cancer Screening for Medicare Beneficiaries; Effectiveness, Costs to Medicare and Medical Resources Required (US Government Prinitng Office, Washington DC, 1987).
85. Shibata, A. & Whittemore, A. S. Re: Prostate cancer incidence and mortality in the United States and the United Kingdom. J. Natl Cancer Inst. 93, 1109-1110 (2001).
86. Crocetti, E., Ciatto, S. & Zappa, M. Prostate cancer: different incidence but not mortality trends within two areas of Tuscany, Italy. J. Natl Cancer Inst. 93, 876-877 (2001).